A wide variety of pharmaceutical products, including pellets, granules, capsules, powders, and crystals are often coated. The procedure of coating tablets is a complex process that results in the forming of a thin layer around the tablet. This layer is in the range of 20 to 200 μm in thickness, or around 1 to 9% of the initial weight of the tablet.
Pharma Excipients
Coating
3D-Printed Tablets of Nifurtimox: In Vitro and In Vivo Anti-Trypanosoma cruzi Studies
Abstract
Background/Objectives: Chagas disease is a neglected tropical disease caused by infection with the parasite Trypanosoma cruzi. Benznidazole and nifurtimox are the only approved drugs for treating this condition, but their low aqueous solubility may lead to erratic bioavailability. This…
Read More...
Read More...
For the good of the patient: Silica & Silicates from Evonik in the pharmaceutical industry
Many challenges – one solution: Fumed silica as well as precipitated silica and silicates from Evonik are some of the most important and highly utilized pharmaceutical excipients. Whether you manufacture medicines for solid, semi-solid or liquid dosing, we support you at every stage of product…
Read More...
Read More...
Patent on pharmaceutical compositions and methods for treating hyperhidrosis
The patent application US20240350420A1 focuses on pharmaceutical formulations and methods for treating conditions such as hyperhidrosis, which involves excessive sweating. The document details the development of modified-release compositions, specifically utilizing Pilocarpine HCl, a muscarinic…
Read More...
Read More...
Utilising terahertz pulsed imaging to analyse the anhydrous-to-hydrate transformation of excipients…
Abstract
Pharmaceutical tablets are routinely film-coated to improve appearance, reduce medication errors and enhance storage stability. Terahertz pulsed imaging (TPI) can be utilised to study the liquid penetration into the porous tablet matrix in real time. Using polymer-coated flat-faced…
Read More...
Read More...
High-dose modified-release formulation of a poorly soluble drug via twin-screw melt coating and…
Abstract
Favipiravir, a high dose antiviral drug effective for oral treatment for COVID-19, with poor water solubility is formulated using a simple, low-cost melt coating and granulation methodology. High-dose (82.5 % w/w API) tablets (600 mg and 800 mg) with desired release profiles are…
Read More...
Read More...
PureCoat® MPA – A Ready-to-prepare film coating systems for moisture-sensitive and hydrophilic…
Sigachi, is one of the leading names in the world of Microcrystalline Cellulose (MCC) manufacturing tailored for Pharmaceutical applications. With a global footprint spanning over 40 countries, Sigachi has been a trusted supplier for over three decades, earning a reputation among top Pharmaceutical…
Read More...
Read More...
FT-NIR models for predicting film quality parameters in titanium dioxide-free tablet coatings
Abstract
This study leverages Fourier Transform Near-Infrared (FT-NIR) spectroscopy to monitor the coating process of pharmaceutical tablets using PVA-based TiO2-free films, with talc and iron oxides as opacifiers. By employing a combination of multivariate analytical techniques to evaluate the…
Read More...
Read More...
Formulation and Evaluation of Enteric Coated Tablets of Serratiopeptidase
Abstract
The present study is aimed at formulating serratiopeptidase enteric coated tablets by utilizing the direct compression method and aqueous solvent-based coating. Seven formulations of serratiopeptidase were developed by using excipients such as Magnesium stearate, Talcum, Primojel, and…
Read More...
Read More...
Enteric coating of halloysite nanotube/ o-butyrylated chitosan microspheres for the co-delivery of…
Abstract
This study aims to achieve co-delivery of paeoniflorin (PF) and butyric acid (BA) to the colon through Eudragit S100 (EUS100)-coated halloysite nanotube/o-butyryl chitosan microspheres (EUS100-HNT-BUCHNPs). O-butyrylated chitosan (BUCH) was prepared by the acylation reaction of chitosan…
Read More...
Read More...
Patent on packaged modified release gamma-hydroxybutyrate formulations having improved stability
The patent WO2019123269A1, titled “Packaged modified release gamma-hydroxybutyrate formulations having improved stability“ presents innovative formulations and packaging methods designed to enhance the dissolution and chemical stability of gamma-hydroxybutyrate (GHB), a treatment for narcolepsy.…
Read More...
Read More...